1st German Phage Symposium—Conference Report

Huber, I.; Potapova, Katerina; Kühn, Andreas; Schmidt, Herbert; Hinrichs, Jörg; Rohde, Christine; Beyer, Wolfgang

doi:10.3390/v10040158

Cited by 6 publications

(7 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there is an ongoing discussion whether or not lytic phages are an alternative to antibiotics in order to combat multi-drug resistant bacteria 54 , a promising strategy appears to be the combined use of both antibacterial agents. Provided that there is no negative interference, the benefit of a simultaneous use can be two-fold: first, bacterial suppression may be stronger as a result of additive or synergistic effects 34 .…”

Section: Discussionmentioning

confidence: 99%

Enhanced antibacterial effect of the novel T4-like bacteriophage KARL-1 in combination with antibiotics against multi-drug resistant Acinetobacter baumannii

Jansen

Wahida

Latz

et al. 2018

Sci Rep

View full text Add to dashboard Cite

The continuing rise of infections caused by multi-drug resistant bacteria has led to a renewed interest in bacteriophage therapy. Here we characterize phage vB_AbaM-KARL-1 with lytic activity against multi-drug resistant clinical isolates of Acinetobacter baumannii (AB). Besides genomic and phenotypic phage analysis, the objective of our study was to investigate the antibacterial outcome when the phage acts in concert with distinct antibiotics. KARL-1 belongs to the family of Myoviridae and is able to lyse 8 of 20 (40%) tested clinical isolates. Its double-stranded DNA genome consists of 166,560 bp encoding for 253 open reading frames. Genome wide comparison suggests that KARL-1 is a novel species within the subfamily Tevenvirinae, sharing 77% nucleotide identity (coverage 58%) with phage ZZ1. The antibacterial efficacy at various multiplicities of infection (MOI) was monitored either alone or in combination with meropenem, ciprofloxacin, and colistin. A complete clearance of liquid cultures was achieved with KARL-1 at an MOI of 10 and meropenem (>128 mg/l). KARL-1 was still effective at an MOI of 10, but antibacterial activity was significantly augmented with meropenem. While ciprofloxacin did generally not support phage activity, the application of KARL-1 at an MOI of 10 and therapeutic doses of colistin significantly elevated bacterial suppression. Hence, KARL-1 represents a novel candidate for use against multi-drug resistant AB and the therapeutic outcome may be positively influenced by the addition of traditional antibiotics.

show abstract

Section: Discussionmentioning

confidence: 99%

Enhanced antibacterial effect of the novel T4-like bacteriophage KARL-1 in combination with antibiotics against multi-drug resistant Acinetobacter baumannii

Jansen

Wahida

Latz

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Due to the wide-spread multidrug resistance of microorganisms, the therapeutic use of bacteriophages has attracted a lot of attention from researchers and practitioners [ 1 ]. A number of research groups in Europe, Asia, and the United States are focusing on creating and maintaining a sufficient concentration of bacteriophages in infection-susceptible skin wounds.…”

Section: Discussionmentioning

confidence: 99%

“…One of the promising and rapidly developing approaches to overcome the increasing antibiotic resistance is the use of bacteriophages, i.e. viruses that infect bacteria and serve as natural regulators of bacterial multiplication [ 1 – 3 ]. In particular, a lot of attention is paid to the fight against hospital wound infections, which, on the one hand, aggravate the patient’s condition, and on the other hand, complicate surgical interventions aimed to close the skin defect.…”

Section: Introductionmentioning

confidence: 99%

Viability of Bacteriophages in the Complex Hydrogel Wound Dressings in vitro

Бесчастнов¹,

Ryabkov²,

Leontiev³

et al. 2021

Sovrem Tehnol Med

View full text Add to dashboard Cite

Using bacteriophages to overcome the increasing resistance of microorganisms to antibiotics is a novel research venue of clinical importance. Among other challenges, this technique is expected to create and maintain an adequate local concentration of bacteriophages at the site of application. In addition, the possibility of combining the phage preparation with antioxidants and anesthetics may provide new options for stimulating the reparative process.The aim of the study was to assess the viability and lytic activity of bacteriophages incorporated into a hydrogel-based wound dressing that contains polyvinyl alcohol, phosphate buffer, with optional additions of succinic acid and lidocaine. Materials and Methods.A technique for incorporating bacteriophages into the complex hydrogel wound dressing ex tempore has been proposed. The bacteriolytic activity of phages inside the hydrogel was determined using standard microbiological techniques. Specifically, we used nutrient media with lawn cultures of Staphylococcus aureus added with the following antibacterial combinations: bacteriophages + succinic acid, bacteriophages + lidocaine, and bacteriophages + succinic acid + lidocaine. The lytic activity of bacteriophages was assessed within 1 to 7 days after the formation of the hydrogel.Results. In all samples containing bacteriophages, the presence of viable and lytically active phages was noted within 1 to 7 days, as evidenced by the "negative colonies" on the culture lawns. On days 1 to 3, no secondary growth was recorded in the phage-containing samples. In hydrogel samples containing phages, succinic acid, and lidocaine, secondary bacterial colonies were detected starting from day 4 indicating some reduction in the lytic activity. Conclusion.The results suggest that bacteriophages immobilized in the hydrogel maintain their viability and lytic activity, and this activity persists when the phages are combined with succinic acid and lidocaine.

show abstract

“…Several attempts were described applying phage in food-producing animals to reduce colonization of the animals with bacterial pathogens, e.g., E. coli, Salmonella spp.Campylobacterspp., Listeria and Serratia spp. [22,129,130].…”

Section: Phage In Food and Surface Decontaminationmentioning

confidence: 99%

Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections

Reuter

Krüger

2020

Virus Genes

View full text Add to dashboard Cite

The emerging occurrence of antibiotic-resistant bacterial pathogens leads to a recollection of bacteriophage as antimicrobial therapeutics. This article presents a short overview of the clinical phage application including their use in military medicine and discusses the genotypic and phenotypic properties of a potential "ideal" therapeutic phage. We describe current efforts to engineer phage for their improved usability in pathogen treatment. In addition, phage can be applied for pathogen detection, selective drug delivery, vaccine development, or food and surface decontamination. Instead of viable phage, (engineered) phage-derived enzymes, such as polysaccharide depolymerases or peptidoglycan-degrading enzymes, are considered as promising therapeutic candidates. Finally, we briefly summarize the use of phage for the detection and treatment of "Category A priority pathogens".

show abstract

1st German Phage Symposium—Conference Report

Cited by 6 publications

References 108 publications

Enhanced antibacterial effect of the novel T4-like bacteriophage KARL-1 in combination with antibiotics against multi-drug resistant Acinetobacter baumannii

Enhanced antibacterial effect of the novel T4-like bacteriophage KARL-1 in combination with antibiotics against multi-drug resistant Acinetobacter baumannii

Viability of Bacteriophages in the Complex Hydrogel Wound Dressings in vitro

Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections

Contact Info

Product

Resources

About